Refine by
Disease Information Articles & Analysis
111 news found
Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development. ...
Insights into this paradigm are expected to link the regulation of pathways to the restoration of immune homeostasis for the treatment of a wide range of diseases, including infectious diseases, autoimmune disorders, allograft rejection and malignancies. ...
Developed in partnership with Thorasys, the Vitalograph tremoflo® C-100 oscillometer helps to detect the presence of small airway impairment, providing additional information to standard pulmonary function tests. It can aid in the diagnosis of asthma and COPD and can also help identify patients who are at risk of progression to COPD. [1] The tremoflo® C-100 assesses ...
WGS and Dante’s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information about personalised dietary choices, predisposition to genetic diseases, genetic carrier information and more. ...
This first-of-its-kind sequencing process, which provides an unparalleled understanding of proteins, will advance drug discovery and diagnostics and bring transformative health and disease insights to the world. Founded by world-renowned scientist, entrepreneur, and National Medal of Technology and Innovation recipient Dr. Jonathan Rothberg, Quantum-Si developed its ...
– AMVUTTRA Demonstrated Halting or Reversal in Neuropathy Impairment with Subcutaneous Administration Once Every Three Months – – Decision Follows Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in July 2022 – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 20, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), ...
Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard electroencephalography (EEG) data to detect electrical disturbances in the brain that may predict cognitive decline and explain variability in disease course for patients with Alzheimer's disease. Pathmanathan's presentation focused on ...
The purpose of the assay, when it becomes clinically available in Q1 2023, will be to enable clinicians to monitor patients’ responses to therapies, including in late-stage cancers for which minimal residual disease (MRD) assays may not be as informative or effective. At this year’s American Association for Cancer Research (AACR) Conference in April, ...
NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease. For more information, visit www.neximmune.com. Forward Looking Statements This press release may contain ...
Despite affecting over 400 million people around the globe, rare diseases have largely been overlooked by traditional drug discovery methods. This is because traditional model often prioritise disease areas where there is a greater understanding of the basic underlying biology and which, in turn, generally come from the larger patient populations associated with more common diseases. This is part ...
Microbial transcriptome and metatranscriptomic information is important for predicting resistance to specific antibiotics, understanding host-pathogen immune interactions, quantifying gene expression changes, and tracking disease progression. ...
NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease. For more information, visit www.neximmune.com. About Zephyr AI Zephyr AI is a high-growth healthcare technology company ...
In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions. For more information about Qualigen Therapeutics, Inc., ...
Salt Lake City, UT – February 25, 2022 – DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the presentation of positive interim data from its ongoing Phase 1/2 clinical trial of IDCT ...
CY6463 is an oral, first-in-class, central nervous system (CNS)-penetrant sGC stimulator that is being developed for neurological and neuropsychiatric diseases associated with cognitive impairment. CY6463 was designed to address multiple pathophysiological features of these disorders. ...
In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions. For more information about Qualigen Therapeutics, Inc., ...
The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. Company and Webcast Information Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. ...
In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions. For more information about Qualigen Therapeutics, Inc., ...
An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients undergoing surgicalAuthors (in order): Halla Nimeiri1, Amanda Young1, Russell Madison1, Alexander Fine1, Ole Gjoerup1, Fotios Loupakis2, Matteo Fassan2,3, Sara Lonardi2, Shruti Sharma4, Hsin-Ta Wu4, Alexey Aleshin4, Elise Renkonen1, Priti Hegde11Foundation Medicine Inc, 2Istituto Oncologico Veneto ...
We look forward to further exploring this approach against this disease, including those tumors that have shown little to no response to standard chemotherapeutic treatments such as gemcitabine,” added Professor Neidle. ...